Pfizer-BioNTech updated COVID shot shows strong immune response in high-risk groups
A total of 100 adults were enrolled in the trial
(Reuters): Pfizer (PFE.N), opens new tab and partner BioNTech (22UAy.DE), opens new tab said on Monday their updated COVID-19 vaccine showed an increased immune response in adults aged 65 and older as well as those aged 18 through 64 with at least one underlying risk condition.
Preliminary data from an ongoing late-stage trial showed at least a four-fold increase in levels of LP.8.1-neutralizing antibody after receiving the updated COVID-19 vaccine, the companies said.
A total of 100 adults were enrolled in the trial.
This study was conducted to provide additional information about immunological effects of the vaccine and is not intended to replace the post-marketing commitments requested by the US health regulator.
How to prepare for a huge disaster when you live in a tiny apartment
- 17 hours ago
Air Chief Marshal Sidhu visits Türkiye, holds high-level meetings with defence leadership
- 6 hours ago
Pakistan seeks breakthrough in US-Iran peace talks
- 4 hours ago
US releases second batch of government declassified UFO files
- 5 hours ago
Volvo teases a new affordable EV to replace discontinued EX30
- 19 hours ago
PM Shehbaz to visit China on four-day official visit from Saturday
- 8 hours ago
CDF Syed Asim Munir departs for Iran on official visit
- 6 hours ago
Hopeful for Iran deal, in constant contact with Pakistan: Marco Rubio
- 4 hours ago
Our national parks are struggling
- 17 hours ago
Elon Musk lost his case against Sam Altman
- 19 hours ago
PCB announces squad for ODI series against Australia
- 9 hours ago
The most important election is the one most Americans skip
- 17 hours ago
